• cardiovascular system;
  • epigenetics;
  • GPCR;
  • kidney;
  • vasoactive intestinal contractor;
  • receptor antagonist

This themed section of the British Journal of Pharmacology contains reviews on recent developments in endothelin research arising from the Twelfth International Conference on Endothelin (ET-12). It includes the emerging role for endothelin-2 in the cardiovascular system, ovarian development, immunology and cancer. The action of endothelin on two key targets is discussed: the paracrine or autocrine regulation of contractility and growth in the heart and the role of endothelin in renal disease. Epidemiological studies have demonstrated cardiovascular disease and circulating levels of endothelin-1 are lower in premenopausal women than in men and evidence is presented for the contribution of sex differences in responses to the peptide. Transcription is the primary level of regulation of the endothelin gene; and current research on the epigenetic regulation of the endothelin pathway, including the silencing of the EDNRB gene encoding the ETB receptor during tumourigenesis, is reviewed.

Linked Articles

This article is part of a themed section on Endothelin. To view the other articles in this section visit To view the previously published paper by Dhaun et al. visit